190 related articles for article (PubMed ID: 27323772)
1. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
Figueiredo CP; Bang H; Cobra JF; Englbrecht M; Hueber AJ; Haschka J; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Rech J; Schett G
Ann Rheum Dis; 2017 Feb; 76(2):399-407. PubMed ID: 27323772
[TBL] [Abstract][Full Text] [Related]
2. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
3. Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.
Ospelt C; Bang H; Feist E; Camici G; Keller S; Detert J; Krämer A; Gay S; Ghannam K; Burmester GR
Ann Rheum Dis; 2017 Jul; 76(7):1176-1183. PubMed ID: 28183721
[TBL] [Abstract][Full Text] [Related]
4. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Rech J; Hueber AJ; Finzel S; Englbrecht M; Haschka J; Manger B; Kleyer A; Reiser M; Cobra JF; Figueiredo C; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Schett G
Ann Rheum Dis; 2016 Sep; 75(9):1637-44. PubMed ID: 26483255
[TBL] [Abstract][Full Text] [Related]
5. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
6. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
[TBL] [Abstract][Full Text] [Related]
7. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
de Moel EC; Derksen VFAM; Stoeken G; Trouw LA; Bang H; Goekoop RJ; Speyer I; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2018 Feb; 20(1):33. PubMed ID: 29482627
[TBL] [Abstract][Full Text] [Related]
8. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
9. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
11. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
[TBL] [Abstract][Full Text] [Related]
12. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
de Moel EC; Derksen VFAM; Trouw LA; Bang H; Collée G; Lard LR; Ramiro S; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2019 Jan; 21(1):28. PubMed ID: 30658699
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis.
Juarez M; Bang H; Hammar F; Reimer U; Dyke B; Sahbudin I; Buckley CD; Fisher B; Filer A; Raza K
Ann Rheum Dis; 2016 Jun; 75(6):1099-107. PubMed ID: 26160441
[TBL] [Abstract][Full Text] [Related]
16. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
Ytterberg AJ; Joshua V; Reynisdottir G; Tarasova NK; Rutishauser D; Ossipova E; Haj Hensvold A; Eklund A; Sköld CM; Grunewald J; Malmström V; Jakobsson PJ; Rönnelid J; Padyukov L; Zubarev RA; Klareskog L; Catrina AI
Ann Rheum Dis; 2015 Sep; 74(9):1772-7. PubMed ID: 24817415
[TBL] [Abstract][Full Text] [Related]
17. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?
Vannini A; Cheung K; Fusconi M; Stammen-Vogelzangs J; Drenth JP; Dall'Aglio AC; Bianchi FB; Bakker-Jonges LE; van Venrooij WJ; Pruijn GJ; Zendman AJ
Ann Rheum Dis; 2007 Apr; 66(4):511-6. PubMed ID: 16984940
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
19. Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease.
Fisher BA; Bang SY; Chowdhury M; Lee HS; Kim JH; Charles P; Venables P; Bae SC
Ann Rheum Dis; 2014 Apr; 73(4):741-7. PubMed ID: 23505239
[TBL] [Abstract][Full Text] [Related]
20. Pitfalls in the detection of citrullination and carbamylation.
Verheul MK; van Veelen PA; van Delft MAM; de Ru A; Janssen GMC; Rispens T; Toes REM; Trouw LA
Autoimmun Rev; 2018 Feb; 17(2):136-141. PubMed ID: 29203292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
